Valeant authorizes $100 million stock repurchase

The board of directors at Southern California's Valeant Pharmaceuticals International approved a $100 million repurchase of its outstanding common stock as part of its 2007 stock repurchase program. 

In a company press release, Valeant's chairperson and CEO J. Michael Pearson said, "The board's authorization of the additional $100 million to the share repurchase program underscores its continued confidence in our strategy and our commitment to enhancing shareholder value." The repurchase will bring the total authorized amount to $300 million. The board approved the first $200 million last June. 

- See Valeant's release
- get more at MSN

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.